Medscape Family Medicine, January 20, 2022 Clinical Advances in Prostate Cancer From ESMO 2021 Prof Johann de Bono discusses prostate cancer data from ESMO 2021, including abiraterone plus ...

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistant prostate cancer ...